Sherif Abou Elela, Ph. D.
Cancer : Biology, Prognosis, and Diagnosis Axis
Centre de recherche du CHUS
Microbiology and Infectiology Department
Faculty of Medicine and Health Sciences
Université de Sherbrooke
Phone | 819 346-1110 ext. 75275
E-Mail | Sherif.Abou.Elela@USherbrooke.ca
Mechanisms of posttranscriptional regulation in eukaryotes
Doctor Sherif Abou Elela’s team aims to understand the basic mechanisms that control the synthesis and stability of RNA in eukaryotic cells in order to understand how genes are regulated. The work of this research team is expected not only to impact our understanding of how genes are regulated but also to lead to the development of new tools for the regulation of gene expression.
Doctor Abou Elela is a member of the Cancer: Biology, Prognosis, and Diagnosis Axis group of the Centre de recherche du CHUS and the RNA group. He is also the director of the Functional Genomics’ Laboratory of the Université de Sherbrooke, the scientific director of the Génome Québec RNomics Platform, and the coordinator of the RiboClub.
Created by Génome Québec, the RNomics Platform offers academic and clinical researchers, as well as national and international industry, the unique opportunity to profile RNA expression and splicing patterns in relation to the disease or phenotype of interest. Current emphasis is now on identifying novel markers for cancer but analysis of other diseases can be easily envisioned. Due to the unique aspect and novelty of the technology developed in Doctor Sherif Abou Elela’s laboratory and used by the RNomics Platform, the Université de Sherbrooke is at the forefront of RNA biology and its diagnostic and therapeutic applications. Genome Canada and Génome Québec have invested over 16 M$ in Doctor Sherif Abou Elela’s research projects and have made his findings available to other scientists through the RNomics Platform.
- Over 60 original publications in high quality scientific journals (PNAS, Cell, NSMB, Current Biology, Cancer Research)
- Functional Annotation of Essential Alternatively Spliced Isoforms, 10 M $ Genome Canada / Génome Québec
- High-throughput Functional Genomics Using Modified Nucleic Acids Technologies (MoNA), 5,8 M $ Genome Canada / Génome Québec
- Identification, profiling and Functional Assignment of the Expressed Genome, 600 K $ Génome Québec
- The mechanisms of RNase III Dependent Post-Transcriptional Gene regulation, CIHR 605 K $ /5 years
- Three patents covering the use of alternative splicing as marker of ovarian and breast cancer
Know-how and Opportunities for Collaboration
- Discovery of splice variants associated with cancer
- Use of splice variants as predictors of ovarian and breast cancer outcome
- Identification of ovarian and breast cancer drug targets
- Discovery and validation of ribosome associated disease
- Identification of phenotypic defects associated with RNA processing and degradation